IBDEI0GV ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,7531,1,4,0)
 ;;=4^N25.1
 ;;^UTILITY(U,$J,358.3,7531,2)
 ;;=^5015616
 ;;^UTILITY(U,$J,358.3,7532,0)
 ;;=E27.49^^52^504^2
 ;;^UTILITY(U,$J,358.3,7532,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7532,1,3,0)
 ;;=3^Adrenocortical Insufficiency,Other
 ;;^UTILITY(U,$J,358.3,7532,1,4,0)
 ;;=4^E27.49
 ;;^UTILITY(U,$J,358.3,7532,2)
 ;;=^5002743
 ;;^UTILITY(U,$J,358.3,7533,0)
 ;;=E72.09^^52^504^4
 ;;^UTILITY(U,$J,358.3,7533,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7533,1,3,0)
 ;;=3^Amino-Acid Transport Disorders,Other
 ;;^UTILITY(U,$J,358.3,7533,1,4,0)
 ;;=4^E72.09
 ;;^UTILITY(U,$J,358.3,7533,2)
 ;;=^5002895
 ;;^UTILITY(U,$J,358.3,7534,0)
 ;;=N25.89^^52^504^22
 ;;^UTILITY(U,$J,358.3,7534,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7534,1,3,0)
 ;;=3^Impaired Renal Tubular Function Disorders,Other
 ;;^UTILITY(U,$J,358.3,7534,1,4,0)
 ;;=4^N25.89
 ;;^UTILITY(U,$J,358.3,7534,2)
 ;;=^5015618
 ;;^UTILITY(U,$J,358.3,7535,0)
 ;;=E26.89^^52^504^11
 ;;^UTILITY(U,$J,358.3,7535,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7535,1,3,0)
 ;;=3^Hyperaldosteronism,Other
 ;;^UTILITY(U,$J,358.3,7535,1,4,0)
 ;;=4^E26.89
 ;;^UTILITY(U,$J,358.3,7535,2)
 ;;=^5002737
 ;;^UTILITY(U,$J,358.3,7536,0)
 ;;=N25.81^^52^504^27
 ;;^UTILITY(U,$J,358.3,7536,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7536,1,3,0)
 ;;=3^Secondary Hyperparathyroidism of Renal Origin
 ;;^UTILITY(U,$J,358.3,7536,1,4,0)
 ;;=4^N25.81
 ;;^UTILITY(U,$J,358.3,7536,2)
 ;;=^5015617
 ;;^UTILITY(U,$J,358.3,7537,0)
 ;;=E22.2^^52^504^26
 ;;^UTILITY(U,$J,358.3,7537,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7537,1,3,0)
 ;;=3^SIADH
 ;;^UTILITY(U,$J,358.3,7537,1,4,0)
 ;;=4^E22.2
 ;;^UTILITY(U,$J,358.3,7537,2)
 ;;=^5002718
 ;;^UTILITY(U,$J,358.3,7538,0)
 ;;=D63.1^^52^505^1
 ;;^UTILITY(U,$J,358.3,7538,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7538,1,3,0)
 ;;=3^Anemia in Chronic Kidney Disease
 ;;^UTILITY(U,$J,358.3,7538,1,4,0)
 ;;=4^D63.1
 ;;^UTILITY(U,$J,358.3,7538,2)
 ;;=^332908
 ;;^UTILITY(U,$J,358.3,7539,0)
 ;;=I12.0^^52^505^9
 ;;^UTILITY(U,$J,358.3,7539,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7539,1,3,0)
 ;;=3^HTN w/ CKD w/ Stage 5 CKD/ESRD
 ;;^UTILITY(U,$J,358.3,7539,1,4,0)
 ;;=4^I12.0
 ;;^UTILITY(U,$J,358.3,7539,2)
 ;;=^5007065
 ;;^UTILITY(U,$J,358.3,7540,0)
 ;;=I95.1^^52^505^10
 ;;^UTILITY(U,$J,358.3,7540,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7540,1,3,0)
 ;;=3^Hypotension,Orthostatic
 ;;^UTILITY(U,$J,358.3,7540,1,4,0)
 ;;=4^I95.1
 ;;^UTILITY(U,$J,358.3,7540,2)
 ;;=^60741
 ;;^UTILITY(U,$J,358.3,7541,0)
 ;;=I95.89^^52^505^11
 ;;^UTILITY(U,$J,358.3,7541,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7541,1,3,0)
 ;;=3^Hypotension,Other
 ;;^UTILITY(U,$J,358.3,7541,1,4,0)
 ;;=4^I95.89
 ;;^UTILITY(U,$J,358.3,7541,2)
 ;;=^5008079
 ;;^UTILITY(U,$J,358.3,7542,0)
 ;;=N17.9^^52^505^12
 ;;^UTILITY(U,$J,358.3,7542,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7542,1,3,0)
 ;;=3^Kidney Failure,Acute,Unspec
 ;;^UTILITY(U,$J,358.3,7542,1,4,0)
 ;;=4^N17.9
 ;;^UTILITY(U,$J,358.3,7542,2)
 ;;=^338532
 ;;^UTILITY(U,$J,358.3,7543,0)
 ;;=N18.5^^52^505^3
 ;;^UTILITY(U,$J,358.3,7543,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7543,1,3,0)
 ;;=3^Chronic Kidney Disease,Stage 5
 ;;^UTILITY(U,$J,358.3,7543,1,4,0)
 ;;=4^N18.5
 ;;^UTILITY(U,$J,358.3,7543,2)
 ;;=^5015606
 ;;^UTILITY(U,$J,358.3,7544,0)
 ;;=N18.9^^52^505^4
 ;;^UTILITY(U,$J,358.3,7544,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7544,1,3,0)
 ;;=3^Chronic Kidney Disease,Unspec
 ;;^UTILITY(U,$J,358.3,7544,1,4,0)
 ;;=4^N18.9
 ;;^UTILITY(U,$J,358.3,7544,2)
 ;;=^332812
 ;;^UTILITY(U,$J,358.3,7545,0)
 ;;=N39.0^^52^505^14
